Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
[HTML][HTML] Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy
K Domvri, P Zarogoulidis, K Darwiche… - Journal of …, 2013 - ncbi.nlm.nih.gov
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
S Dhillon - Targeted oncology, 2015 - Springer
Gefitinib (Iressa®) is a selective small-molecule epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally …
tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
[HTML][HTML] Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
Y Liu, Y Zhang, G Feng, Q Niu… - Experimental and …, 2017 - spandidos-publications.com
The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …
Extending survival of stage IV non-small cell lung cancer
S Carnio, S Novello, T Mele, MG Levra… - Seminars in oncology, 2014 - Elsevier
Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with
locally advanced or metastatic disease. In this setting the goal of treatment is to prolong …
locally advanced or metastatic disease. In this setting the goal of treatment is to prolong …
[HTML][HTML] Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta …
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - Springer
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy …
Y Wang, RQ Li, YQ Ai, J Zhang, PZ Zhao, YF Li… - Clinical and …, 2015 - Springer
Objective To determine whether the specific genotype of exon 19 deletion has a better
survival outcome than that of exon 21 substitution in advanced lung adenocarcinoma with …
survival outcome than that of exon 21 substitution in advanced lung adenocarcinoma with …
Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
Y Yuan, XF Li, JQ Chen, CX Dong… - OncoTargets and …, 2014 - Taylor & Francis
Past studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors can significantly improve clinical outcomes in patients with locally …
kinase inhibitors can significantly improve clinical outcomes in patients with locally …